AMYPAD
LightNews LightNews
banner
imi-amypad.bsky.social
AMYPAD
@imi-amypad.bsky.social
110 followers 120 following 25 posts
Research initiative aiming to improve the understanding, diagnosis & management of Alzheimer's disease. Our project was funded by @ihieurope.bsky.social

https://amypad.eu/
Posts Replies Media Videos
imi-amypad.bsky.social
Interested to learn how to maximise your project’s regulatory impact? Register for this online event hosted by @ihieurope.bsky.social ⤵️
www.ihi.europa.eu/news-events/...

Gill Farrar will highlight the regulatory value that our AMYPAD Biomarker Qualification Opinion brought to the amyloid PET field
ihieurope.bsky.social Innovative Health Initiative @ihieurope.bsky.social · 7d
🔬 Do you want to better understand what #RegulatoryImpact means & how to achieve it with your IMI or IHI project? 🚀 Join us on 10 Dec at 14:00 & find out! Hear from @ema.europa.eu regulators & past projects
👉 link.europa.eu/vGdQrY
#IHITransformingHealth #HealthResearch #EUResearch #RegulatoryScience
Join us on 10 Dec for Regulatory Impact: What it is and how to achieve it.
November 17, 2025 at 8:02 AM
imi-amypad.bsky.social
📢 Check out this perspective review, highlighting the advancements brought by blood biomarkers in Alzheimer's disease🧠🩸

doi.org/10.1002/alz....
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD), the question arises whether these can replace the accepted reference standard, ...
doi.org
October 15, 2025 at 9:07 AM
imi-amypad.bsky.social
We were pleased to join an exciting symposium during #EANM25 last week in Barcelona focused on advancing early diagnosis with PET imaging and biomarkers.

Lyduine Collij shared AMYPAD insights and spoke alongside Prof. Dr. Alexander Drzezga and Prof. dr. Silvia Morbelli.

amypad.eu/news/recent-...
October 15, 2025 at 8:40 AM
imi-amypad.bsky.social
📢 NEW paper out in Alzheimer's & Dementia, using data from the AMYPAD Prognostic and Natural History Study!

Congratulations to all authors 👏

alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning
INTRODUCTION The emergence, stability, and contributing factors of Alzheimer's disease (AD) gray matter subtypes remain unclear. METHODS We analyzed data from 1323 individuals without a diagnosis ...
alz-journals.onlinelibrary.wiley.com
October 15, 2025 at 8:36 AM
imi-amypad.bsky.social
🚀 We’re pleased to announce the release of the latest edition of our newsletter, featuring the release of the AMYPAD raw dataset, highlights from the Euro-PAD symposium and new papers!

👉 Read the full newsletter here: mailchi.mp/e602ab237ff7...
September 26, 2025 at 6:46 AM
imi-amypad.bsky.social
📣NEW AMYPAD out!

The genetic data harmonisation manuscript for the AMYPAD consortium is online in Alzheimer's & Dementia!

Authors provide a detailed pipeline for genotype array data QC, imputation, harmonisation, and PRS computation⤵️

doi.org/10.1002/alz....
Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium
INTRODUCTION We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their as.....
doi.org
September 15, 2025 at 10:30 AM
imi-amypad.bsky.social
📣 #AAIC25 is around the corner!

Whether you’ll be on-site in Toronto or joining online, don’t miss the AMYPAD presentations 👇

For more information about the conference, please visit: aaic.alz.org
July 25, 2025 at 10:48 AM
imi-amypad.bsky.social
📢 NEW AMYPAD paper out in European Journal of Neurology assessing the cost-utility of early versus no amyloid-PET in the diagnostic work-up of memory clinic patients after 6 months. @ihieurope.bsky.social

Congratulations to all authors 👏

doi.org/10.1111/ene....
Utility, Costs and Cost‐Utility of Amyloid‐PET in the Diagnostic Process of Memory Clinic Patients: A Trial‐Based Economic Evaluation From AMYPAD‐DPMS
Background Amyloid positron emission tomography (PET) is instrumental in achieving an accurate diagnosis and may help to limit health-seeking behavior. Currently, amyloid-PET is not routinely used i...
doi.org
June 24, 2025 at 7:57 AM
Reposted by AMYPAD
barcelonabeta.bsky.social
This past two days, we hosted the Euro-PAD symposium to discuss the latest advancements in neuroimaging and biomarkers for #Alzheimer’s disease, as well as to share updates from the Euro-PAD initiative over the past year. ⤵️

www.barcelonabeta.org/en/news/news...
June 18, 2025 at 8:09 AM
imi-amypad.bsky.social
📣Yesterday and today, the Euro-PAD community convened in Barcelona for a scientific symposium hosted by @barcelonabeta.bsky.social.

👉Almost 100 participants gathered to discuss the latest advancements in neuroimaging and biomarkers for Alzheimer’s disease!

amypad.eu/news/recent-...
June 17, 2025 at 6:44 AM
Reposted by AMYPAD
barcelonabeta.bsky.social
This morning, before the symposium, we held two parallel workshops, one led by #BBRC researchers focused on fluid biomarkers and the other led by
@acealzheimercenter.com focused on clinical trials
June 16, 2025 at 2:57 PM
Reposted by AMYPAD
barcelonabeta.bsky.social
Today and tomorrow we are hosting the EuroPAD 2025 symposium!

#EuroPAD seeks to enhance and extend late-stage biomarker cohorts focused on Alzheimer’s, with the specific aim of establishing the most extensive and deeply phenotyped longitudinal cohort of at-risk individuals.
June 16, 2025 at 2:53 PM
Reposted by AMYPAD
ihieurope.bsky.social
📢 JUST PUBLISHED: Paper in @natrevdrugdiscov.nature.com on how to maximise #RegulatoryImpact from public-private partnerships, co-authored by IHI’s Nathalie Seigneuret. Check out 3 examples to follow from C-Path & @imi-amypad.bsky.social
👇 Read it below 👇
#IHITransformingHealth #RegulatoryScience
natrevdrugdiscov.nature.com Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · Jun 10
Delivering regulatory impact from consortium-based projects www.nature.com/articles/d41...

This new article by authors @cpathinstitute.bsky.social & @ihieurope.bsky.social‬ discusses how consortia developing new tools to support decision making by regulatory agencies could maximise their impact
Screenshot of article
June 12, 2025 at 9:13 AM
imi-amypad.bsky.social
📣New paper out highlighting lessons learned that could help maximise the regulatory impact of consortium-based projects.

C-Path and AMYPAD are featured as examples of projects that have achieved regulatory successes

👉https://www.nature.com/articles/d41573-025-00098-8
Delivering regulatory impact from consortium-based projects
Multiple consortia have been established in the past two decades with the aim of tackling roadblocks in the development of medical products, often by developing new tools to support decision making by...
www.nature.com
June 16, 2025 at 9:19 AM
imi-amypad.bsky.social
NEW paper out entitled "Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study"

Congratulations to all authors 👏

Check it out now⤵️

link.springer.com/article/10.1...
Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study - European Journal of Nucle...
Purpose Amyloid PET imaging is capable of measuring brain amyloid load in vivo. The aim of this study is to assess the relationship of the baseline amyloid with its accumulation over time and with cog...
link.springer.com
April 28, 2025 at 7:38 AM
imi-amypad.bsky.social
📢Exciting news! We're pleased to announce that the AMYPAD raw dataset is now available for data access requests on the Alzheimer's Disease Data Initiative's Workbench!

➡️ Visit the AMYPAD website for more information: amypad.eu/data/
April 22, 2025 at 12:09 PM
imi-amypad.bsky.social
👉Leo Pieperhoff presented findings from the AMYPAD PHNS study at #ADPD2025 today!

The harmonised data are available on the #ADWorkbench of the Alzheimer’s Disease Data Initiative. Interested to learn more? Visit Booth 16 of the Alzheimer’s Disease Data Initiative at #ADPD2025!
April 2, 2025 at 12:35 PM
imi-amypad.bsky.social
🧠 #ADPD2025 DAY 2!

Join us in Room Hall F2 today at 13:50 for the symposium “WHITE MATTER ALTERATIONS”.

Leonard Pieperhoff will be presenting AMYPAD results “Grey/White Matter Contrast Alterations Precede Amyloid Positivity and Atrophy Markers.”

Don’t miss his insightful presentation 🙌
April 2, 2025 at 9:08 AM
imi-amypad.bsky.social
🚨#ADPD2025 is officially underway!

This morning Mario Tranfa, Luigi Lorenzini and Emma Luckett presented data from the AMYPAD, EPAD and Euro-PAD consortiums!

Natàlia Vilor Tejedor also presented the #ADWorkbench at the session hosted by the Alzheimer's Disease Data Initiative!
April 1, 2025 at 11:48 AM
imi-amypad.bsky.social
✨ Today marks the start of #ADPD2025 in Vienna!

If you're attending the conference, don’t miss the AMYPAD, EPAD and EUROPAD-related talks.

We hope to see you there to catch up on our latest advancements 🙌
April 1, 2025 at 9:08 AM
imi-amypad.bsky.social
👉 Earlier today, we were pleased to present insights from the AMYPAD project at #ECCN2025 during a satellite symposium, sponsored by Life Molecular Imaging!

Thanks to everyone who joined us and contributed to the discussion ☺️
March 25, 2025 at 1:54 PM
imi-amypad.bsky.social
📣 Check out this new article providing a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use.

Congratulations to all authors 👏

doi.org/10.1002/alz....
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and t...
doi.org
March 24, 2025 at 2:15 PM
imi-amypad.bsky.social
🌟Good morning #ECCN25!

Join us tomorrow for the AMYPAD satellite symposium "What does AMYPAD study reveal about centiloid relevance for the future clinical setting?"

We're looking forward to seeing you!
March 24, 2025 at 10:08 AM
imi-amypad.bsky.social
If you are attending next week #ECCN25 in Madrid, don’t miss the AMYPAD satellite symposium on Tuesday, 25th March at 12:30.

This session will explore the AMYPAD study's impact on centiloid relevance and its implications for future clinical practices.
March 17, 2025 at 10:08 AM
imi-amypad.bsky.social
✨The #ADPD2025 conference is just one month away in Vienna!

AMYPAD, EPAD and EUROPAD will be presenting their latest insights in Alzheimer's disease research! We can't wait to see you there! 🙌
March 3, 2025 at 10:08 AM